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Adult hippocampal neuroplasticity triggers susceptibility to
recurrent depression
ND Alves1,2, JS Correia1,2, P Patrício1,2, A Mateus-Pinheiro1,2, AR Machado-Santos1,2, E Loureiro-Campos1,2, M Morais1,2, JM Bessa1,2,
N Sousa1,2 and L Pinto1,2
Depression is a highly prevalent and recurrent neuropsychiatric disorder associated with alterations in emotional and cognitive
domains. Neuroplastic phenomena are increasingly considered central to the etiopathogenesis of and recovery from depression.
Nevertheless, a high number of remitted patients experience recurrent episodes of depression, remaining unclear how previous
episodes impact on behavior and neuroplasticity and/or whether modulation of neuroplasticity is important to prevent recurrent
depression. Through re-exposure to an unpredictable chronic mild stress protocol in rats, we observed the re-appearance of
emotional and cognitive deﬁcits. Furthermore, treatment with the antidepressants ﬂuoxetine and imipramine was effective
to promote sustained reversion of a depressive-like phenotype; however, their differential impact on adult hippocampal
neuroplasticity triggered a distinct response to stress re-exposure: while imipramine re-established hippocampal neurogenesis
and neuronal dendritic arborization contributing to resilience to recurrent depressive-like behavior, stress re-exposure in
ﬂuoxetine-treated animals resulted in an overproduction of adult-born neurons along with neuronal atrophy of granule neurons,
accounting for an increased susceptibility to recurrent behavioral changes typical of depression. Strikingly, cell proliferation arrest
compromised the behavior resilience induced by imipramine and buffered the susceptibility to recurrent behavioral changes
promoted by ﬂuoxetine. This study shows that previous exposure to a depressive-like episode impacts on the behavioral and
neuroanatomical changes triggered by subsequent re-exposure to similar experimental conditions and reveals that the proper
control of adult hippocampal neuroplasticity triggered by antidepressants is essential to counteract recurrent depressive-like
episodes.
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INTRODUCTION
Major depression is a prevalent neuropsychiatric disorder affecting
around 16% of the population worldwide, which experiences one
or several episodes of depression during their lifetime.1 Despite
the moderate capacity to achieve remission, over 85% of remitted
patients suffer recurrent episodes of depression, within 15 years
after an initial event.2,3 Although a ﬁrst episode has been mostly
linked to stressful events,4 recurrent depression has also been
associated to the persistence of subclinical residual symptoms and
the number of previous episodes.5 Nevertheless, these evidences
rely on the risk to develop recurrence and not on the
determinants of recurrence or relapse events. In this context, it
is of the upmost importance to understand the biological
mechanisms underlying the precipitation of recurrent episodes
and determine the behavioral traits prone to re-appear.
Over the years, few efforts have been made to study the impact
of repeated stress exposure. Recently, the deleterious effects
evoked by re-exposure to stress were associated to altered
expression of cytoskeletal proteins.6 Furthermore, other studies
revealed that animals subjected to stress during adolescence were
resilient to depressive- and anxiety-like behavior on chronic stress
re-exposure in adulthood7 and abrogation of hippocampal
neurogenesis in adolescence blocked susceptibility to chronic
social defeat in adulthood.8
Still, the neuroplastic capacity of the adult brain, observed in
regions such as the hippocampus, was not yet associated to
resilience or susceptibility to recurrent depression. In this brain
region, highly sensitive to the detrimental effects of stress,
neuroplastic events, including adult cytogenesis (neurogenesis9–11
and gliogenesis12) and morphological changes, are described to
be altered by chronic stress and reverted by antidepressants
(ADs).13,14 Neuroplastic processes, and particularly its distur-
bances, have behavioral repercussions in cognitive and emotional
dimensions in both physiological15 and pathological conditions
including schizophrenia16 and depressive disorders.17–19 Also,
previous studies indicate that, at short-term, behavioral
improvements induced by ADs rely on hippocampal neuronal
remodeling,9 while at long-term, remission is mainly associated to
a normalized production of newborn neurons in the adult
hippocampal dentate gyrus (DG).20
Therefore, it is crucial to understand the impact of recurrent
stress in behavior and neuroplastic processes and the importance
of modulating neuroplasticity in the prevention of recurrent
episodes of depression. As such, in this work, we assessed
behavioral alterations induced by recurrent stress and the impact
of typical ADs, ﬂuoxetine and imipramine, by repeated exposure
to unpredictable chronic mild stress (uCMS) protocol. Also, to
evaluate the relevance of hippocampal cytogenesis in the effects
of ADs, a subset of animals was simultaneously treated with
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methylazoxymethanol (MAM), a cytostatic agent that artiﬁcially
blocks cell proliferation.9,20–22 We observed that pre-treatment
with ﬂuoxetine or imipramine confers a different proﬁle of
response to stress re-exposure, which relies on their distinct
impact in adult hippocampal neuroplasticity.
MATERIALS AND METHODS
A brief description of the materials and methods is presented in this
section. For a full description, please refer to the Supplementary
Information.
Animals
Experiments were conducted in adult male (2 months old) Wistar Han rats
(Charles River Laboratories, L'Arbresle, France) housed and kept under
standard laboratory conditions at 22 ± 1 ºC, 55% relative humidity, 12 h
light/dark cycle, food and water ad libitum. Rats (n= 6–8 for behavioral
analysis, of which three to four were considered for gene expression
quantiﬁcation, immunoﬂuorescence and neuromorphologic studies) from
two independent sets were randomly divided into six groups, next
described in detail. All the procedures were conducted in accordance with
EU Directive 2010/63/EU and the Portuguese National Authority for animal
experimentation, Direção-Geral de Alimentação e Veterinária.
uCMS and drug treatments
Rats were subjected to a validated uCMS protocol for 6 weeks, as
previously described9,20,23 and detailed in the Supplementary Information.
Similarly to previous studies,9,20 in the last 2 weeks, animals were daily
injected intraperitoneally with saline (SAL) or with ADs to induce
behavioral recovery either with ﬂuoxetine (FLX; 10 mg kg− 1, Kemprotec,
Middlesbrough, UK) or imipramine (IMIP; 10 mg kg− 1; Kemprotec).
Subgroups of animals, treated with ADs were co-administered with MAM
(7 mg kg− 1; MRI Global Chemical Carcinogen Repository, Kansas City, MO,
USA; subcutaneously). Simultaneously, a group of animals not exposed to
uCMS, were also injected with saline (CTRL). All groups received during
7 days (4 days before and 3 days after the cessation of the ﬁrst uCMS
protocol) intraperitoneal injections of bromodeoxyuridine (BrdU,
50 mg kg− 1; Sigma-Aldrich, St. Louis, MO, USA) to label newly adult-born
cells generated immediately after ADs treatment. For the following 4 weeks
after uCMS, animals were not subjected to any stressor. Afterwards,
animals were re-exposed to a slight modiﬁed version of the uCMS protocol,
detailed in the Supplementary Information, to avoid habituation to
stressors.
Behavioral analysis
Along the experimental protocol, behavior was continuously monitored for
depressive- and anhedonic-like behavior, anxiety and cognition (Figure 1a).
At weeks 6, 10 and 16, animals were submitted to the sucrose preference
test and sweet-drive test to assess anhedonic-like behavior and the novel
object recognition for cognition. Anxiety-like behavior was assessed at
week 6 through the elevated-plus maze and at weeks 10 and 16 by the
novelty-suppressed feeding. At the end of the protocol, additional tests
were performed: forced-swimming test for depressive-like behavior and
the Morris water maze for cognition.
Quantiﬁcation of hippocampal newborn cells survival and
neuronal morphometric analysis
Conditions and antibodies used in immunostaining for neurogenesis
analysis was performed as described in detailed in Supplementary
Information. Dendritic morphology of granule neurons from the dorsal
DG was assessed by the Golgi-Cox method. Dendritic length and neuronal
branching were analyzed as detailed in Supplementary Information.
RT-PCR measurements
The mRNA expression levels of neuroplasticity-related genes were
measured by qRT-PCR, as previously described.24 Total RNA was isolated
from macrodissected DG using the Direct-zol RNA MiniPrep (Zymo
Research, Irvine, CA, USA) according to the manufacturer’s instructions.
Obtained RNA (500 ng) was reverse transcribed using qScript cDNA SuperMix
(Quanta Biosciences, Gaithersburg, MA, USA). Beta-2-Microglobulin (B2M)
was used as internal standard for normalization of the target gene’s
expression. Genes analyzed and respective sequences are detailed in
Supplementary Information. Real-time reactions were performed in
Applied Biosystems 7500 Fast-Real Time PCR System (Applied Biosystems,
Foster City, CA, USA) using 5 × HOT FIREPol EvaGreen qPCR Mix Plus (ROX)
(Solis Biodyne, Tartu, Estonia). Relative gene expression was calculated
using the ΔΔCt method. The results are presented as relative expression to
the standard gene.
Statistical analysis
Statistical analysis was performed using GraphPad Prism 6.0 (GraphPad
Software, La Jolla, CA, USA). The animals were randomly assigned in
experimental groups. The sample sizes were based on previous published
studies.9,20 All presented data satisﬁed normal distribution in Kolmogorov–
Smirnov testing. After conﬁrmation of homogeneity of group variances
between the groups, data were subjected to appropriate statistical tests.
Student’s t-test was used for statistical comparisons between two groups
when appropriate. The comparison between stressed groups was evaluated
using one-way analysis of variance. Analysis of variance repeated measures
was used to analyze cognitive learning tasks performance and Sholl
analysis. Descriptive statistical results are presented as mean± s.e.m.
Differences between groups were determined by Bonferroni’s post hoc
multiple comparison test and statistical signiﬁcance was set at Po0.05. No
data points were excluded from the different analyses.
RESULTS
Non-treated and ﬂuoxetine-treated animals, but not imipramine-
treated animals, are behaviorally susceptible to recurrent uCMS
exposure
To assess the impact of recurrent uCMS exposure and the
relevance of ADs treatment, behavior domains typically affected
by stress were monitored throughout the protocol (time points
(tp) 1–3; Figure 1a), including depressive-like behavior, anxiety and
cognition. As previously shown,9,25 exposure to uCMS elicited an
anhedonic state manifested by decreased sucrose preference in
the sucrose preference test that was reverted by both ﬂuoxetine
and imipramine treatment (tp1, P= 0.0008; F2,14 = 15.21,
P= 0.0003; FLX: post hoc P= 0.0003; IMIP: post hoc P= 0.0033,
Figure 1b). This effect was preserved after a 4-week stress-free
period (tp2). Spontaneous recovery of anhedonic behavior was
also achieved in uCMS non-treated animals (P40.1, Figure 1c).
Strikingly and contrarily to other studies,6 uCMS re-exposure to
non-treated animals did not promote the re-appearance of
anhedonic-like behavior (tp3: P40.1, Figure 1d); the same
resilience was observed in animals treated with imipramine
during the ﬁrst uCMS exposure. However, and in accordance to
previous reports,6 treatment with ﬂuoxetine conferred suscept-
ibility to anhedonic-like behavior as denoted by the signiﬁcantly
decreased sucrose preference (F2,14 = 16.11, P= 0.0002; FLX: post
hoc P= 0.0003; IMIP: post hoc P40.1, Figure 1d). These alterations
in the anhedonic-like proﬁle were corroborated by the recently
developed sweet-drive test26 (Supplementary Figures 1a and b).
Nevertheless, immobility time in the forced-swimming test, a
typical surrogate measure of depressive-like behavior, was
signiﬁcantly increased after repeated uCMS exposure (Figure 1e),
suggesting the re-appearance of depressive-like behavior in
non-treated animals (Po0.01), similarly to those treated with
ﬂuoxetine (F2,14 = 7.078, P= 0.0075; FLX: post hoc P40.1;
Figure 1e). In contrast, the treatment with imipramine successfully
prevented the re-appearance of depressive-like behavior after
uCMS re-exposure (IMIP: post hoc P= 0.0112, Figure 1e).
When tested for anxiety traits, uCMS exposure increased
anxiety-like behavior in the elevated-plus maze as previously
described,9,20 which was partially rescued by both ADs (tp1:
P= 0.0071; F2,14 = 3.264, P= 0.0686; FLX: post hoc P= 0.0981; IMIP:
post hoc P40.1, Figure 1f). Following a 4-week stress-free period,
no signs of anxiety-like behavior were observed in the novelty-
suppressed feeding test in both non-treated and treated animals
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Figure 1. Anhedonic- and anxiety-like behaviors induced by recurrent stress exposure are prevented by imipramine treatment, but not
ﬂuoxetine. (a) Schematic representation of the experimental timeline used, including behavioral assessments throughout the protocol and the
respective treatments. (b–d) Longitudinal assessment of anhedonic-like behavior by the SPT, revealed an increased susceptibility after re-
exposure to stress driven by ﬂuoxetine. (e) Assessment of behavioral despair, at the end of the experimental protocol, by the FST test revealed
that recurrent stress exposure induced a signiﬁcant increase of immobility time, only prevented in animals treated with imipramine. (f–h)
Anxiety-like behavior was continuously tested throughout the experimental protocol, at week 6 by the EPM (f) and the NSF at weeks 10 (g)
and 16 (h), evidencing the efﬁcacy of imipramine in preventing anxiety-like behavior after stress re-exposure, contrarily to ﬂuoxetine. (i) Non-
treated and particularly, ﬂuoxetine-treated animals, subjected to repeated uCMS exposure presented elevated corticosterone levels in the
serum. Basal corticosterone levels were measured in the serum of rats collected between 0800 and 0900 at the end of the protocol. See also
Supplementary Figures 1 and 2. *Denotes the effect of uCMS analyzed by Student’s t-test; #Denotes the effect of ADs, by comparison of
treatment and SAL animals; and ‡denotes differences between ADs, analyzed by one-way analysis of variance (ANOVA). Data are represented
as mean± s.e.m. #P⩽ 0.05, **, ##P⩽ 0.01, ***, ###, ‡‡‡P⩽ 0.001; n= 6–8 animals per group. uCMS, unpredictable chronic mild stress protocol
(uCMS*, slightly modiﬁed version. See Supplementary Information). AD, antidepressant; CTRL, non-stressed animals; EPM, elevated-plus maze;
FLX, animals repeatedly exposed to uCMS and treated with ﬂuoxetine; FST, forced-swimming test; IMIP, animals repeatedly exposed to uCMS
and treated with imipramine; MWM, Morris water maze; NOR, novel object recognition; NSF, novelty-suppressed feeding; SAL, animals
repeatedly exposed to uCMS and non-treated; SDT, sweet-drive test; SPT, sucrose preference test; TP, time point.
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(tp2, Figure 1g). However, uCMS re-exposure promoted the re-
emergence of an anxious-like phenotype in non-treated (tp3:
Po0.001) but also in ﬂuoxetine-treated animals (F2,12 = 8.786,
P= 0.0045; FLX: post hoc P40.1). In contrast, imipramine-treated
animals did not display signs of anxiety-like behavior after uCMS
re-exposure (IMIP: post hoc P= 0.0048, Figure 1h). No changes in
food consumption were observed among groups (Supplementary
Figures 2a and b). The analysis of plasma corticosterone levels in
blood serum, after uCMS re-exposure, revealed elevated levels
in non-treated (Po0.001) and ﬂuoxetine-treated animals
(F2,9 = 26.40, P= 0.0002; FLX: post hoc P= 0.0040, Figure 1i), when
compared with non-stressed animals, whereas imipramine-treated
animals presented corticosterone levels similar to the non-
stressed group (IMIP: post hoc P= 0.0288, Figure 1i). In addition,
as stress dysregulates cognitive functions that depend on the
structural integrity of the hippocampus, prefrontal cortex and
reciprocal connections between these two regions, cognitive
performance was also assessed (Figure 2). We observed that
cognition was signiﬁcantly affected by uCMS exposure, as it
decreased novel object exploration in the novel object recognition
test (tp1, P= 0.0011, Figure 2a); notably, such impairment in long-
term memory was signiﬁcantly reversed by imipramine (tp1,
F2,36 = 3.566, P= 0.0386; FLX: post hoc P= 0.6358; IMIP: post hoc
P= 0.0340, Figure 2a). Four weeks after cessation of the uCMS
protocol, no cognitive deﬁcits were observed in any experimental
group (tp2, Figure 2b). However, uCMS re-exposure elicited the re-
appearance of long-term memory deﬁcits by decreasing novel
object exploration in non-treated and ﬂuoxetine-treated animals,
but not imipramine-treated animals (tp3, P= 0.0001; F2,29 = 1.482,
Po0.0001; FLX: post hoc P40.99; IMIP: post hoc P= 0.0001,
Figure 2c). Moreover, and despite no alterations in spatial working
memory in the Morris water maze test (Figure 2d), uCMS re-
exposure induced deﬁcits in the reference memory task,
particularly evident in the third day of the test (Figure 2e). In
concordance, signiﬁcant differences were observed for learning
slope (P= 0.0164) and area under the curve latency (P= 0.0267;
Figure 2e). In this speciﬁc task, treatment with ﬂuoxetine or
imipramine prevented such cognitive deﬁcits (Figure 2e). Inter-
estingly, impairments in spatial behavioral ﬂexibility promoted by
uCMS re-exposure in non-treated animals (P= 0.0018, Figure 2f)
Figure 2. Evaluation of cognitive function throughout the experimental protocol revealed that imipramine is able to prevent cognitive deﬁcits
induced by recurrent stress exposure while ﬂuoxetine speciﬁcally prevents alterations in behavior ﬂexibility. (a–c) Continuous assessment of
long-term memory using the novel object recognition (NOR) test revealed that recurrent stress induces cognitive deﬁcits, which are also
observed in ﬂuoxetine-treated animals but not with imipramine treatment. (d–g) At the end of the protocol, the MWM test was used to
evaluate cognitive performances, including working (d) and reference memory (e), reversal learning (f) and working memory by a probe trial
(g). *Denotes the effect of uCMS analyzed by Student’s t-test; #Denotes the effect of ADs, by comparison of treatment and SAL animals; and
‡denotes differences between ADs analyzed by one-way analysis of variance (ANOVA). ANOVA repeated measures was used to analyze
cognitive learning tasks performance. Data are represented as mean± s.e.m. *, #P⩽ 0.05, **, ##, ‡‡P⩽ 0.01, ***, ###, ‡‡‡P⩽ 0.001; n= 6–8 animals per
group. AD, antidepressant; AUC, area under the curve; CTRL, non-stressed animals; FLX, animals repeatedly exposed to uCMS and treated with
ﬂuoxetine; IMIP, animals repeatedly exposed to uCMS and treated with imipramine; MWM, Morris water maze; NOR, novel object recognition;
SAL, animals repeatedly exposed to uCMS and non-treated; TP, time point; uCMS, unpredictable chronic mild stress protocol.
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were only prevented by ﬂuoxetine, but not by imipramine
(F2,13 = 7.521, P= 0.0068; FLX: post hoc P= 0.0264; IMIP: post hoc
P40.1, Figure 2f). Analysis of the probe trial for learning ﬂexibility
assessment also evidenced the impairments induced by repeated
uCMS exposure (P= 0.0257, Figure 2g). Prior treatment with
ﬂuoxetine or imipramine blocked the emergence of cognitive
deﬁcits on the probe trial (F2,13 = 9.241, P= 0.0032; FLX: post hoc
P= 0.0032; IMIP: post hoc P= 0.0484, Figure 2g).
Stress re-exposure differently affects the generation of DG
newborn neurons by ADs
The impact of recurrent uCMS exposure and AD treatment in the
process of adult neurogenesis was next assessed through the
quantiﬁcation of cell proliferation and newborn cells survival. No
statistical differences were observed in the hippocampal cell
proliferation or newborn cells in non-treated uCMS re-exposed
animals, as well as in the imipramine-treated animals, in com-
parison with nonstressed animals (BrdU+: P= 0.1792, F2,6 = 4.435,
P= 0.0657; IMIP: post hoc P40.1, Figure 3a; BrdU+NeuN+:
P= 0.1584, F2,5 = 8.381, P= 0.0253; IMIP: post hoc P40.1,
Figures 3b and c). On the other hand, the treatment with
ﬂuoxetine tends to increase the number of BrdU+ cells (FLX: post
hoc P= 0.0795; Figure 3a) and induced a signiﬁcant increase of
newborn neurons in the adult DG, identiﬁed as BrdU+NeuN+ cells
(FLX: post hoc P= 0.0319; Figures 3b and c). Interestingly, this
effect was neuronal-speciﬁc, as no alterations were found in the
number of newborn astroglial cells (identiﬁed as BrdU+GFAP+
cells; Figures 3d and e) and in the expression analysis of astroglial
differentiation promoting factors, STAT3 and BMP4 (Figure 3f). In
addition, quantiﬁcation of the number of progenitor cells revealed
no alterations in the number of Ki-67+ proliferating cells among
groups (Figure 3g), but a signiﬁcant decrease in the number of Ki-
67+Sox-2+ progenitor cells in ﬂuoxetine-treated animals was
observed (F2,7 = 9.642, P= 0.0097; FLX: post hoc P= 0.0106,
Figures 3h and i). Moreover, recurrent uCMS exposure produced
a signiﬁcant decrease in the number of neuroblasts, revealed by a
decreased number of Ki-67+DCX+ (P= 0.0186, Figures 3j and k),
and also evidenced by the decreased gene expression of
NEUROD1 and DCX (NEUROD1: P= 0.0088; DCX: P= 0.0481,
Figure 3l). Fluoxetine-treated animals also presented a marked
decrease in the number of neuroblasts, contrarily to those treated
Figure 3. Treatment with ﬂuoxetine boosts the generation and survival of newborn hippocampal neurons even after recurrent exposure to
stress. (a and b) Quantiﬁcation of the number of BrdU+ and BrdU+NeuN+ cells, per dentate gyrus (DG) area, revealed an increased production
and survival of newborn neurons evoked by ﬂuoxetine treatment. (c) Representative coronal section of the DG stained for BrdU (in red), NeuN
(in green) and DAPI (in blue). (d) Density of newborn astroglial cells, identiﬁed as BrdU+GFAP+ cells, revealed no major effect of stress or ADs
treatment. (e) Representative staining for BrdU (in red), GFAP (in green) and DAPI (in blue) in hippocampal DG. (f) Analysis of relative
expression levels of STAT3 (upper panel) and BMP4 (lower panel) in the macrodissected DG corroborated the absence of major effects on
gliogenesis in consequence of the recurrent stress exposure or AD treatment. (g and h) Quantitative analysis of Ki-67+ cells and amplifying
progenitors, identiﬁed as Sox-2+Ki-67+ cells, revealed that ﬂuoxetine leads to a depletion of DG progenitor cells. (i) Representative confocal
image of Sox-2 (green) and Ki-67 (red) immunostaining. (j) Analysis of the number of DCX+Ki-67+ cells, representative of the neuroblasts
population in the DG showed that animals subjected to repeated stress exposure, non-treated and treated with ﬂuoxetine, presented a
decreased number of neuroblasts. (k) Coronal section of the DG stained for DCX (in green), Ki-67 (in red) and DAPI (in blue). (l) Relative mRNA
expression levels of NEUROD1 (upper panel) and DCX (lower panel) in the macrodissected DG revealed a decrease in the expression levels as a
consequence of repeated stress exposure. In general, treatment with ADs restored the expression levels of both makers of neuronal
maturation. Scale bars represent 30 μm. *Denotes the effect of unpredictable chronic mild stress (uCMS) analyzed by Student’s t-test; #denotes
the effect of ADs, by comparison of treatment and SAL animals, analyzed by one-way analysis of variance (ANOVA). Data represented as
mean± s.e.m. *, #P⩽ 0.05; n=± 4 animals per group. AD, antidepressant; CTRL, non-stressed animals; FLX, animals repeatedly exposed to
uCMS and treated with ﬂuoxetine; IMIP, animals repeatedly exposed to uCMS and treated with imipramine; SAL, animals repeatedly exposed
to uCMS and non-treated.
Neuroplasticity sets recurrence in depression
ND Alves et al
5
Translational Psychiatry (2017), 1 – 10
with imipramine (Figure 3j). Surprisingly, ﬂuoxetine treatment
tends to revert the decreased expression of NEUROD1 and DCX
induced by recurrent stress (NEUROD1: F2,6 = 5.759, P= 0.0402;
FLX: post hoc P= 0.0509; DCX: F2,8 = 5.170, P= 0,0362; FLX: post hoc
P= 0.0419, Figure 3l).
Effect of recurrent stress on neuronal morphology depends on AD
treatment
In addition to hippocampal neurogenesis, changes in dendritic
remodeling and synaptic plasticity of granule neurons were also
assessed. Three-dimensional morphological analysis revealed that,
although stress re-exposure in non-treated animals did not affect
neuronal arborization, animals pre-treated with ﬂuoxetine pre-
sented signiﬁcant dendritic atrophy (Figures 4a and c). Conversely,
imipramine-treated animals, on stress re-exposure presented a
robust increase in neuronal dendritic arborization (F2,8 = 19.70,
P= 0.0008; FLX: post hoc P= 0.0429; IMIP: post hoc P= 0.0286,
Figures 4a and c). In accordance, Sholl analysis revealed a reduced
complexity of granule neurons in ﬂuoxetine-treated animals,
whereas imipramine promoted an overall increase in dendritic
arborization (Figure 4b). Even though no major effect of stress re-
exposure on neuronal atrophy was observed, gene expression
analysis of neuroplastic-related genes revealed a marked decrease
of NCAM (P= 0.0002) and SYN1 (P= 0.0027) expression, suggesting
deﬁcits in synaptic plasticity. Of notice, ﬂuoxetine treatment was
able to prevent changes in the expression of SYN1 and
imipramine prevented alterations in the expression of both NCAM
and SYN1 (NCAM: F2,13 = 4.890, P= 0.0261; FLX: post hoc P= 0.3926;
IMIP: post hoc P= 0.0240; SYN1: F2,14 = 22.64, Po0.001; FLX: post
hoc P= 0.001; IMIP: post hoc Po0.001, Figures 4d and e).
Proliferation arrest blocks the behavioral effects of ADs after uCMS
re-exposure
To examine the requirement of adult hippocampal neurogenesis
to mediate behavioral outcomes promoted by ADs in recurrent
depression, a subgroup of ADs-treated animals was co-
administered with MAM, for cell proliferation blockage, during
the last 2 weeks of the ﬁrst uCMS exposure (Figure 5a). Of notice,
as previously observed,20,22,27 cell proliferation arrestment by
MAM impacts anxiety-like behavior of non-stressed animals
(Supplementary Figure 3). As expected, MAM administration in
animals re-exposed to uCMS and co-treated with ﬂuoxetine
induced a signiﬁcant reduction in the number of BrdU+NeuN+
cells, preventing the increased neurogenesis promoted by
ﬂuoxetine (FLX vs FLX+MAM: P= 0.0303, Figure 5b). Concerning
imipramine, co-treatment with MAM elicited signiﬁcantly lower
levels of neurogenesis, similar to those observed in stressed non-
treated animals (IMIP vs IMIP+MAM: P= 0.0153, Figure 5b).
Figure 4. Imipramine enhances dentate gyrus (DG) neuronal arborization, whereas ﬂuoxetine promotes an atrophy of granule neurons after
recurrent stress. Dendritic length analysis (a) and neuronal organization (b) of DG granule neurons showed a dendritic shrinkage promoted by
ﬂuoxetine treatment, whereas imipramine induced an enlargement of the neuronal arborization after stress re-exposure. (c) Representative
three-dimensional (3D) morphometric reconstruction of DG granule neurons of each experimental group. (d and e) The relative gene
expression levels of remodeling genes, NCAM and SYN1, corroborates the neuronal remodeling promoted by imipramine treatment. Scale
bars represent 50 μm. *Denotes the effect of unpredictable chronic mild stress (uCMS) analyzed by Student’s t-test. #Denotes the effect of ADs,
by comparison of treatment and SAL animals; and ‡denotes differences between ADs, analyzed by one-way analysis of variance (ANOVA).
ANOVA repeated measures was used to analyze Sholl analysis. Data are represented as mean± s.e.m. #, ‡P⩽ 0.05, **, ‡‡P⩽ 0.01, ***, ###,
‡‡‡P⩽ 0.001; n=± 4 animals per group. AD, antidepressant; CTRL, non-stressed animals; FLX, animals repeatedly exposed to uCMS and treated
with ﬂuoxetine; IMIP, animals repeatedly exposed to uCMS and treated with imipramine; SAL, animals repeatedly exposed to uCMS and non-
treated.
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Further assessment of anhedonic-like behavior by the sweet-
drive test after uCMS re-exposure revealed that neurogenesis
arrestment prevented anhedonic-like signs observed in animals
co-treated with ﬂuoxetine during the ﬁrst uCMS exposure (FLX
+MAM: post hoc P40.1, Figure 5c). Remarkably, cell proliferation
arrest led to the appearance of anhedonic-like behavior in animals
co-treated with imipramine (IMIP+MAM: post hoc Po0.001,
Figure 5c). In addition, the MAM treatment prevented anxiety-
like signs promoted by ﬂuoxetine (F2,22 = 15.70, Po0.001; FLX:
post hoc P40.1; FLX+MAM: post hoc P= 0.0134, Figure 5d) while it
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compromised the therapeutic protection conferred by imipramine
for this behavioral dimension, leading to an anxious-like state
(IMIP: post hoc P= 0.017; IMIP+MAM: post hoc P40.1, Figure 5d).
Despite the importance of cell genesis modulation for the AD
effects on emotional behaviors, results of the Morris water maze
revealed that cell proliferation blockage by MAM had no
signiﬁcant effect on the cognitive performance of animals treated
either with ﬂuoxetine or imipramine (Figures 5e and f).
DISCUSSION
In the present work, using a well-established animal model of
depression, we studied how re-exposure to chronic stress impacts
in emotional, anxiety and cognitive behaviors. Noticeably, we
showed that recurrent uCMS exposure potentiated the re-
appearance of depressive- and anxiety-like behaviors as well as
cognitive deﬁcits. In accordance to previous reports, we observed
that treatment with ﬂuoxetine and imipramine promoted a
sustained remission of an initial depressive-like state and a re-
establishment of the hippocampal neurogenic process.20 How-
ever, uCMS induces persistent morphological, namely synaptic,
and behavioral scars that are observed even 4 weeks post stress
exposure. These residual changes, together with reported impair-
ments in DG synaptic plasticity9,28,29 may account for the re-
appearance of depressive, anxiety and cognitive deﬁcits on uCMS
re-exposure. Strikingly, our results also show that the impact of an
initial uCMS, followed by a recovery period, increases animals’
ability to cope with uCMS re-exposure in particular behavioral
traits, such as anhedonia. These animals present intact DG
dendritic length and no alterations in the survival of newborn
neurons, which may account for the observed resilience to
anhedonic-like deﬁcits. However, the contribution of other brain
regions, such as the nucleus accumbens, cannot be excluded of
this anhedonic resilience, given the previous association between
stress-induced anhedonia and medium spiny neurons hypertro-
phy at the nucleus accumbens.25
We next studied how treatment with typical ADs, ﬂuoxetine and
imipramine, during the ﬁrst depressive-like episode, would impact
in further recurrent episodes and, in addition, understand the
importance of pro-neuroplastic effects triggered by ADs to
prevent recurrent depression. Results revealed that animals
treated with ﬂuoxetine during the initial uCMS exposure
presented an increased susceptibility to anhedonic-like behavior
once re-exposed to uCMS, in contrast to non-treated animals,
which did not present an anhedonic phenotype. Moreover,
treatment with ﬂuoxetine was inefﬁcient in preventing the
detrimental behavioral consequences induced by stress re-
exposure, including depressive- and anxiety-like behavior as well
as cognitive deﬁcits (long-term memory) with the exception of a
speciﬁc cognitive task (behavioral ﬂexibility). Interestingly, these
results seem to be in accordance with animal studies reporting
behavioral deﬁcits in ﬂuoxetine-treated animals re-exposed to
stress6 and in agreement with clinical studies showing that
remitted patients treated with ﬂuoxetine present higher rates of
relapse, in comparison with other ADs.30,31 Interestingly,
co-administration of MAM and ﬂuoxetine prevented the
re-emergence of anhedonic- and anxiety-like behavior triggered
by uCMS re-exposure. This observation suggests that the
abnormal potentiation of cell proliferation and sustained increase
in the number of adult-born neurons promoted by ﬂuoxetine,
previously described,9,20 is most likely triggering the increased
susceptibility to anhedonic-like behavior and contributing to the
depressive- and anxiety-like phenotype induced by uCMS re-
exposure (Figure 5g). In fact, an aberrant increase in the
generation of newborn neurons was shown to enhance plasticity
and excitability,32 increase the competition for afferent inputs33
and depolarization in response to GABA-ergic inputs.34 Conse-
quently, such alterations promote an increased participation of
these cells during learning and memory tasks35 and a reconﬁgura-
tion of DG-CA3 circuits that degrade stored memories.36 More-
over, previous studies have shown an increased anxiety-like
phenotype in consequence of increased neurogenesis induced by
voluntary wheel running.37–39 In this context, our ﬁndings
reinforce the view that re-establishment of adult hippocampal
neurogenesis is required for a sustained remission from
depressive-like behavior20 and that production and survival of
adult-born neurons beyond a certain threshold can be detrimental
for normal hippocampal function. Importantly, previous studies
also suggested a strong impact of hippocampal structural
alterations in the susceptibility to depression40 and an important
contribution for recurrent episodes.41 Noticeably, in consequence
of the higher recruitment of cells for differentiation caused by
ﬂuoxetine treatment, we also observed, as expected, a strong
depletion in the number of progenitor cells and neuroblasts in the
hippocampal DG. Despite the attempt to potentiate the neuro-
genic process, denoted by the increased expression of neuronal
maturation-related markers, ﬂuoxetine treatment was not able to
restore the levels of neuronal differentiation possibly due to the
depletion of neural progenitors. Besides boosting adult neurogen-
esis, ﬂuoxetine treatment and further stress re-exposure also
induced dendritic atrophy of the DG granule neurons, similar to
the immediate effects induced by uCMS protocol in non-treated
animals.9 Altogether, the non-physiological potentiation of
neurogenesis and the neuronal atrophy promoted by ﬂuoxetine
may trigger increased susceptibility to behavioral deﬁcits in stress
recurrence, as shown here. Strikingly, ﬂuoxetine-treated animals
Figure 5. Ablation of adult hippocampal neurogenesis by MAM rescues behavioral deﬁcits induced by ﬂuoxetine in recurrent stress while
inhibiting the protective effects promoted by imipramine. (a) Representative scheme of the experimental timeline used, including drug
treatments with ADs and MAM. (b) Quantiﬁcation of the number of BrdU+NeuN+ cells in the hippocampal dentate gyrus (DG), representing
the population of newborn neurons denotes that proliferation arrest promotes a normalization of adult neurogenesis in consequence of
treatment with ﬂuoxetine, whereas a depletion in the levels of neurogenesis in animals treated with imipramine occurred. (c) The assessment
of anhedonic-like behavior by the SDT, at the end of the protocol, revealed that the arrestment of adult neurogenesis rescues the anhedonic
phenotype presented by ﬂuoxetine-treated animals and inhibits the effect of imipramine to prevent anhedonic alterations. (d) Anxiety-like
behavior, tested by the EPM, demonstrated that ablation of adult hippocampal neurogenesis has a preventive effect on anxiety-induced
ﬂuoxetine while leading to an anxious-like state when MAM was co-treated with imipramine. (e and f) MWM performed to assess cognitive
performance on working memory revealed no major effects of MAM treatment in this behavioral dimension. (g) Schematic representation of
the impact of adult neuroplasticity alterations promoted by unpredictable chronic mild stress (uCMS) and ADs. #Denotes the effect of ADs, by
comparison of treatment and SAL animals and ‡denotes differences between ADs, analyzed by one-way analysis of variance (ANOVA). ANOVA
repeated measures was used to analyze cognitive learning tasks performance. Data are represented as mean± s.e.m. #, ‡P⩽ 0.05, ##, ‡‡P⩽ 0.01,
###, ‡‡‡P⩽ 0.001; n= 6–8 animals per group. AD, antidepressant; CTRL, non-stressed animals; EPM, elevated-plus maze; FLX, animals repeatedly
exposed to uCMS and treated with ﬂuoxetine; FLX+MAM, animals repeatedly exposed to uCMS and treated with ﬂuoxetine and
methylazoxymethanol; IMIP, animals repeatedly exposed to uCMS and treated with imipramine; IMIP+MAM, animals repeatedly exposed to
uCMS and treated with imipramine and methylazoxymethanol; MAM, methylazoxymethanol; MWM, Morris water maze; SAL, animals
repeatedly exposed to uCMS and non-treated; SDT, sweet-drive test.
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where resilient to a speciﬁc cognitive task, namely spatial reversal
learning, that was compromised in non-treated animals. This
particular cognitive task is not exclusively associated with
hippocampal function but also the prefrontal cortex,42 namely
the prelimbic and infralimbic, and orbitalfrontal regions;43 thus,
there is the possibility that ﬂuoxetine treatment may positively
affect these prefrontal regions accounting to the observed
resilience of reversal learning deﬁcits. Contrastingly, treatment
with imipramine conferred protection to uCMS re-exposure in the
majority of behavioral domains assessed, including cognitive, and
anxiety-like behavior. This behavioral resilience to repeated uCMS
was associated with a normalization of the hippocampal
neurogenic process,20 but also with a robust increase in the
dendritic arborization of DG granule neurons (Figure 5g). In fact,
the maintenance of adult neurogenesis at certain levels was
required to prevent behavior deﬁcits induced by recurrent stress,
as the suppression of cell genesis by co-administration of MAM
prevented the resilience to behavioral alterations on treatment
with imipramine. In addition, and in line with previous studies
demonstrating that ADs, including imipramine, reverse the
shrinkage in dendritic branching induced by stress and allows
the re-establishment of the normal neuronal network,9 we here
suggest that the observed long-term increase in the arborization
of DG granule neurons also accounts for the increased resistance
to repeated stressful events. Accordingly, it has been proposed
that adaptation to stress driven by neuronal structural alterations
is a source of resilience that, when absent, contributes to the onset
and recurrence of neuropsychiatric disorders, such as
depression.44,45 Likewise, imipramine is also known to confer
protection to depressive-like behavior through an increase in the
dendritic arborization of immature neurons.46 It is plausible that
the distinct effects promoted by ﬂuoxetine and imipramine, in
case of re-exposure to stress, could be linked to their differential
impact on neural cell types14 and/or to their distinct selectivity to
neuronal receptors. The latter hypothesis could be explored in
future studies through the speciﬁc blockage of the noradrenergic
component on treatment with imipramine.
This study shows that a recurrent stress exposure promotes the
re-appearance of anxiety and cognitive deﬁcits. Moreover, these
behavioral alterations were correlated with normal levels of
survival of newborn neurons with exception of synaptic plasticity
that showed persistent impairments after recurrent stress
exposure. Our ﬁndings put forward the understanding how
previous stressful events may have short-term detrimental effects
on cortico-limbic plasticity but also highlight their importance in
conferring protection against certain behavioral and neuroplastic
deﬁcits after recurrent stressful situations. In addition, the present
work is the ﬁrst to show that abnormal adult neuroplasticity
triggers distinct responses to recurrent exposure to uCMS: an
exaggerated potentiation of adult neurogenesis and neuronal
atrophy increases the susceptibility to speciﬁc behavioral deﬁcits
induced by recurrent stress exposure, whereas normalization of
adult neurogenesis, and an enhancement of dendritic arboriza-
tion, confers protection to recurrent depression. In essence, these
ﬁndings reﬂect how adult neuroplasticity changes induced by
stress and ADs must be ﬁnely tuned to prevent recurrence in
depression.
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